Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment

Exploring the repertoire of peptides presented on major histocompatibility complexes (MHCs) helps identify targets for immunotherapy in many hematologic malignancies. However, there is a paucity of such data for diffuse large B-cell lymphomas (DLBCLs), which might be explained by the profound downre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourne, Christopher M., Mun, Sung Soo, Dao, Tao, Aretz, Zita E. H., Molvi, Zaki, Gejman, Ron S., Daman, Andrew, Takata, Katsuyoshi, Steidl, Christian, Klatt, Martin G., Scheinberg, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327544/
https://www.ncbi.nlm.nih.gov/pubmed/35561310
http://dx.doi.org/10.1182/bloodadvances.2021006069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327544/
https://www.ncbi.nlm.nih.gov/pubmed/35561310
http://dx.doi.org/10.1182/bloodadvances.2021006069

Ejemplares similares